How Healthy Volunteer Studies can Accelerate Oncology Drug D...
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD; Senior Directors Scientific Affairs,...
Blog
Key Clinical Pharmacology Studies to Support Biologic Drug R...
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD; Senior Directors Scientific Affairs,...
Blog
12 Questions to Help Guide Renal Impairment PK Study Design
By Sabina Paglialunga, PhD Director Scientific Affairs, Celerion Need to run a renal impairmen...
Blog
Adaptive Trial Designs
Flexibility of Adaptive Early Phase Study Designs Sabina Paglialunga, PhD Director, Scientifi...
Blog
A Decade of Innovative Technology to Accelerate Drug Develop...
Celerion continues its Celebration of Translating Science into Medicine for over a decade by highlig...
Blog
The Platforms and Promise of COVID-19 Vaccines
by Sabina Paglialunga, PhD - Director, Scientific Affairs, Celerion COVID-19 is a highly infectio...
Blog
Celebrating a Decade of Biosimilars Development
Biosimilars are not an exact copy but are similar to the originally approved biological product. Fol...
Blog
Open for Business: Early Phase Clinical Drug Development dur...
The global COVID-19 pandemic has altered the mechanics of nearly every industry. For early phase cli...
Blog
COVID-19, Kawasaki and the Cytokine Storm
by Sabina Paglialunga, PhD - Director, Scientific Affairs, Celerion SARS-CoV-2 symptoms include feve...